2 reports

“Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight” report by PNS Pharma gives comprehensive clinical insight on 37 biosimilar version of Lantus drug in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially available in India, Japan, Kenya, Czech Republic, Estonia, Germany, China, Slovakia, United...

  • Recombinant Insulin
  • China
  • Japan
  • Estonia
  • Germany
  • Kenya
  • India
  • Czech Republic
  • Slovakia
  • United Kingdom

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein...

  • Protein Therapy
  • Biopharmaceutical
  • Recombinant Insulin
  • China